Global gene expression profiling is useful for elucidating a drug's mechanism of action on the liver; however, such profiling in rats is not very sensitive for predicting human drug-induced liver injury, while dedifferentiated monolayers of primary human hepatocytes (PHHs) do not permit chronic drug treatment. In contrast, micropatterned cocultures (MPCCs) containing PHH colonies and 3T3-J2 fibroblasts maintain a stable liver phenotype for 4-6 weeks. Here, we used MPCCs to test the hypothesis that global gene expression patterns in stable PHHs can be used to distinguish clinical hepatotoxic drugs from their non-liver-toxic analogs and understand the mechanism of action prior to the onset of overt hepatotoxicity. We found that MPCCs treated with the clinical hepatotoxic/non-liver-toxic pair, troglitazone/rosiglitazone, at each drug's reported and non-toxic C max (maximum concentration in human plasma) for 1, 7, and 14 days displayed a total of 12, 269, and 628 differentially expressed genes, respectively, relative to the vehicle-treated control. Troglitazone modulated >75% of transcripts across pathways such as fatty acid and drug metabolism, oxidative stress, inflammatory response, and complement/coagulation cascades. Escalating rosiglitazone's dose to that of troglitazone's C max increased modulated transcripts relative to the lower dose; however, over half the identified transcripts were still exclusively modulated by troglitazone. Last, other hepatotoxins (nefazodone, ibufenac, and tolcapone) also induced a greater number of differentially expressed genes in MPCCs than their non-liver-toxic analogs (buspirone, ibuprofen, and entacapone) following 7 days of treatment. In conclusion, MPCCs allow evaluation of time-and dose-dependent gene expression patterns in PHHs treated chronically with analog drugs.
Prediction of drug-induced liver injury (DILI) in humans during preclinical drug testing is critically important since DILI remains a leading cause of drug attrition in the marketplace (Kaplowitz, 2005) . However, animals are <50% predictive of human DILI (Olson et al., 2000) , potentially due to significant species-specific differences in drug metabolism pathways (Shih et al., 1999) . Therefore, several in vitro models of the human liver have been developed for investigating DILI . Atlhough cancerous and immortalized cell lines as well as precision-cut liver slices are available for incorporating into various culture platforms, primary human hepatocytes (PHHs) are considered to be the "gold standard" for in vitro drug screening since they are relatively simple to use in medium-to high-throughput culture formats and contain the full complement of enzymes/cofactors required for drug metabolism (Godoy et al., 2013) .
In contrast to pure PHH monolayers that display a rapid decline in phenotypic functions , coculture of PHHs with both liver-and non-liver-derived nonparenchymal cells (NPCs) can transiently stabilize major liver functions (Bhatia et al., 1999) . Further exercising precise control over homotypic interactions between PHHs and their heterotypic interactions with 3T3-J2 murine embryonic fibroblasts can enhance the PHH phenotype and stabilize it for 4-6 weeks as compared with low levels of functions and a premature functional decline in randomly distributed cocultures of the same two cell types (Khetani and Bhatia, 2008) . This so-called "micropatterned coculture" (MPCC) platform has also been shown to induce high levels of cytochrome P450 (CYP450) and phase II conjugation enzyme activities for 4þ weeks in cryopreserved PHHs from multiple donors, which enables on-demand drug screening . Such long-term functional stability of MPCCs allows for repeat treatment with drugs, which has proven useful for improving the sensitivity of DILI detection over acute treatment in conventional PHH monolayers . In particular, when treated with 54 clinical hepatotoxins and 10 nonliver-toxins for up to 9 days, human MPCCs were found to have approximately 78% sensitivity and 90% specificity when measuring ATP and glutathione levels in cell lysates, and albumin secretion and urea synthesis in culture supernatants. Such sensitivity in MPCCs for DILI detection was an approximately 2-to 3-fold improvement over the treatment of collagen/Matrigel sandwiched PHH cultures with the same set of drugs for 24 h (Xu et al., 2008) . However, the use of a limited number of functional end-points in the aforementioned studies did not provide detailed mechanistic insights into diverse pathways of the liver that are affected by the hepatotoxins relative to their non-toxic structural analogs.
In contrast to a limited number of functional end-points, global gene expression profiling has proven useful to identify the mechanism of action of hepatotoxins (Barros and Martin, 2008) . One goal of such a toxicogenomic (TGx) analysis is to identify genes that are candidate biomarkers of adverse effects of drugs, which could be modulated prior to the onset of overt cellular toxicity, as is the case for the majority of patients who are treated with approved drugs and do not experience severe DILI. However, TGx studies in rats have suffered from a lack of sensitivity for predicting human DILI (Kienhuis et al., 2009; Zhang et al., 2012b) , while such studies in conventional PHH cultures have been restricted to short-term (days) treatment with high drug doses due to a decline in PHH gene expression levels and functions (Harris et al., 2004; Kier et al., 2004; Uehara et al., 2008) . Such short-term treatment of PHH cultures with hepatotoxic/ non-liver-toxic drug analogs may not fully capture the diverse pathways that are differentially affected when PHHs are treated repeatedly over several weeks. We set out to test this hypothesis by using MPCCs. In particular, MPCCs were treated for 1, 7, and 14 days with dimethylsulfoxide (DMSO), troglitazone (hepatotoxin), or rosiglitazone, the non-liver-toxic structural analog of troglitazone, at the drugs' respective C max , the maximum drug concentration reported in human plasma. Functions (WST-1, albumin secretion, urea synthesis, and CYP3A4 activity) and global gene expression profiles (via Affymetrix whole genome human microarrays) in MPCCs were assessed at each timepoint to determine the effects of each drug relative to the DMSO control. Next, we evaluated global gene expression profiles in MPCCs treated for 7 days with troglitazone and rosiglitazone at the same concentration to determine drug-specific versus concentration-specific effects. Finally, MPCCs were treated for 7 days with 3 additional pairs of clinical hepatotoxins and nonliver-toxins (nefazodone/buspirone, ibufenac/ibuprofen, and tolcapone/entacapone) and gene expression changes were compared with those obtained in MPCCs treated with troglitazone/ rosiglitazone.
MATERIALS AND METHODS
Fibroblast culture. 3T3-J2 murine embryonic fibroblasts were obtained from Howard Green at Harvard University (Rheinwald and Green, 1975) . These fibroblasts were maintained in high glucose Dulbecco's Modified Eagle's Medium (DMEM; Corning Life Sciences, Tewksbury, Massachusetts) with 10% (v/v) bovine serum (Thermo Fisher Scientific, Waltham, Massachusetts), and 1% (v/v) penicillin/streptomycin (Corning Life Sciences) solution. The fibroblasts were passaged no more than 12 times prior to use in cocultures with hepatocytes as described below.
Establishment of MPCCs. Cryopreserved PHHs were purchased from vendors permitted to sell products derived from human organs procured in the United States of America by federally designated organ procurement organizations (BioreclamationIVT, Baltimore, Maryland, and Triangle Research Labs-now part of Lonza, Durham, North Carolina). The PHH donors used in this study included JNB (19-year-old Caucasian female with a history of lupus who died of intracranial hemorrhage secondary to stroke) from BioreclamationIVT, and HUM4043 (6-month-old Caucasian female who died of anoxia/blunt injury) and HUM4055A (54-year-old Caucasian female who died of stroke) from Triangle Research Labs. The JNB donor was used for all studies except for qPCR validation (HUM4043) and the additional structural drug analog pairs (HUM4055A), as also specified in the captions of each figure.
PHHs were thawed, counted, and assessed for viability per the manufacturers' instructions. MPCCs were created as previously described . Briefly, adsorbed rat tail collagen I (Corning Life Sciences) was lithographically patterned in each well of a 24-well plate to create 500 mm diameter circular domains spaced 1200 mm apart, center-to-center. PHHs selectively attached to the collagen domains leaving approximately 25 000 attached PHHs on approximately 90 collagen-coated islands within each well of a 24-well plate. 3T3-J2 murine embryonic fibroblasts were seeded 18-24 h later at approximately 90 000 cells per well in a 24-well plate to create MPCCs. Hepatocyte culture medium containing a high glucose DMEM (Corning Life Sciences) base was replaced on MPCCs every 2 days (300 ml/well for a 24-well plate). Other components of the culture medium have been described previously in March et al. (2015) . The morphology of MPCCs was monitored using an EVOS FL cell imaging system (Thermo Fisher Scientific) with phase contrast objectives.
Drug treatment. Troglitazone, rosiglitazone, ibufenac, ibuprofen, tolcapone, and entacapone were purchased from Cayman Chemical (Ann Arbor, Michigan), while nefazodone and buspirone were obtained from Sigma-Aldrich (St Louis, Missouri). All drugs were dissolved in 100% DMSO (Corning Life Sciences). The reported C max values for the drugs were obtained from published studies (Dewland et al., 2009; Xu et al., 2008) . After allowing the MPCCs to functionally stabilize for approximately 1 week, the cultures were treated in serum-free hepatocyte culture medium for 24 h, 7 days, or 14 days with DMSO at 0.1% (v/v), troglitazone at its reported C max (2.82 mg/ml), or rosiglitazone at its C max (0.373 mg/ml). Additional MPCCs were treated for 7 days with rosiglitazone at troglitazone's C max (2.82 mg/ml), nefazodone at its reported C max (434.55 ng/ml), buspirone at its C max (2.11 ng/ml), ibufenac at its C max (19.23 mg/ml), ibuprofen at its C max (31.87 mg/ml), tolcapone at its C max (4.51 mg/ml), or entacapone at its C max (1.91 mg/ml). Fresh drug was administered with media changes every other day for the duration of the study. The DMSO concentration that MPCCs were exposed to was kept at 0.1% (v/v) relative to the culture medium for all conditions tested since increasing levels of DMSO in culture medium are known to cause a downregulation of CYP3A4 in PHHs (Easterbrook et al., 2001) , which may alter the toxicity profiles of drugs.
Biochemical assays. Albumin levels in collected cell culture supernatants were measured using an enzyme-linked immunosorbent assay (MP Biomedicals, Irvine, California) with horseradish peroxidase detection and 3,3 0 ,5,5 0 -tetramethylbenzidine (Fitzgerald Industries, Concord, Massachusetts) as the substrate, while urea levels were measured using a colorimetric endpoint assay utilizing diacetyl monoxime with acid and heat (Stanbio Labs, Boerne, Texas) (Khetani and Bhatia, 2008) . CYP3A4 enzyme activity was measured by first incubating cultures with substrate (luciferin-IPA from Promega Life Sciences, Madison, Wisconsin) for 1 h at 37 C and then detecting the luminescence of produced metabolite (luciferin) on a Synergy H1 multi-mode reader (Biotek, Winooski, Vermont) according to manufacturer's protocols. Cell viability was assessed with the WST-1 kit from Roche Life Science (Indianapolis, Indiana). CYP3A4, urea, and WST-1 assays were conducted on the same culture wells.
Gene expression assays. Total RNA was isolated and purified using the RNeasy mini kit (Qiagen, Valencia, California) and genomic DNA was digested using DNase-I (New England Biolabs, Ipswich, Massachusetts). RNA samples were then sent to the Whitehead Institute (Cambridge, Massachusetts) or the University of Illinois at Chicago Core Genomics Facility where they were inspected for quality, hybridized to Affymetrix GeneChip Human Genome U133 Plus 2.0 microarrays, and quantified using previously published protocols (Khetani and Bhatia, 2008) . Control RNA samples from pure 3T3-J2 cultures treated for 7 days with either DMSO or troglitazone (2.82 mg/ml) were also hybridized to the U133 Plus 2.0 human microarrays in order to determine which transcripts were called "present" due to the mouse RNA and would thus constitute noise in the analysis. For each experiment, one microarray was used per condition due to the cost-prohibitive nature of microarray experiments. Instead, 8 total drugs (4 hepatotoxic/ non-liver-toxic pairs) were used to reach the main conclusions of the study. All Affymetrix microarray data utilized in this study have been submitted to the Gene Expression Omnibus (GEO accession: GSE85180). For qPCR, approximately 10 ll of purified RNA was reverse transcribed into complementary DNA (cDNA) using the high capacity cDNA reverse transcription kit (Thermo Fisher Scientific). Then, 250 ng of cDNA was added to each qPCR reaction along with predesigned Solaris (GE Healthcare Dharmacon, Lafayette, Colorado) human-specific primer/probe sets according to manufacturer's protocols. The primer/probe sets were selected to be human-specific without cross-reactivity to 3T3-J2 mouse DNA and included: stearoyl-CoA desaturase (SCD), acylCoA synthetase medium chain family member 3 (ACSM3), elongation of very long chain fatty acids 2 (ELOVL2), cluster of differentiation 36 (CD36), mannose-binding lectin 2 (MBL2), FBJ murine osteosarcoma viral oncogene homolog (FOS), chromosome 10 open reading frame 10 (C10orf10), and high mobility group 20B (HMG20B). Some of these transcripts showed >2-fold upregulation (SCD, ACSM3, ELOVL2, CD36, MBL2) or <2-fold change (FOS, C10orf10, HMG20B) in troglitazone-treated MPCCs relative to DMSO controls from the Affymetrix microarray data and were thus used as a validation set in another donor of PHHs (HUM4043). Hepatic gene expression was normalized to the housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH). qPCR was performed on a MasterCycler RealPlex-2 (Eppendorf, Hamburg, Germany).
Data analysis.
Raw intensity values on the Affymetrix microarrays were normalized, modeled, and compared using the DNA Chip Analyzer software (Li and Wong, 2001) . Data from all chips were normalized to MPCCs treated with DMSO for 7 days (invariant set normalization). Probe sets marked as "present" on the 3T3-J2-only control chip were omitted from further analysis. Differentially expressed genes upon treatment of MPCCs with troglitazone or rosiglitazone at each time-point were defined as those transcripts with a jfold changej > 2.0 and jdifference in expressionj > 100 in drug-treated MPCCs relative to DMSO-only controls. For the other drug pairs for which another PHH donor was used in MPCCs, a jfold changej > 1.5 and jdifference in expressionj >50 were used as filtering criteria to ensure a sufficient number of differentially expressed genes for analysis as compared with the aforementioned selection criteria for troglitazone and rosiglitazone. Then, the Database for Annotation, Visualization, and Integrated Discovery (DAVID) was used to identify Kyoto Encyclopedia of Genes and Genomes (KEGGs) pathways and gene ontology (GO) processes from the differentially expressed gene sets (Huang et al., 2009) . Data from biochemical and qPCR assays were analyzed and graphed using Microsoft Excel and GraphPad Prism (La Jolla, California).
RESULTS

Treatment of MPCCs for Up to 2 Weeks With Troglitazone or
Rosiglitazone PHH morphology and functions. Overall viability in MPCCs (JNB donor), as assessed by the cleavage of WST-1 to formazan by cellular mitochondrial dehydrogenases (not specific to hepatocytes), was not significantly altered over 2 weeks of treatment with troglitazone or rosiglitazone at their respective C max values as compared with treatment with 0.1% (v/v) DMSO ( Figure 1A ). Furthermore, hepato-specific urea ( Figure 1B ) secretion was also not significantly affected in drug-treated MPCCs relative to MPCCs treated with DMSO over 2 weeks. On the other hand, both rosiglitazone-and troglitazone-induced CYP3A4 activity in MPCCs by approximately 2.5-and 9-fold of DMSO controls, respectively, following 1 week of treatment ( Figure 1C ). Following 2 weeks of treatment, the fold induction had increased to approximately 17.5-and 50-fold for rosiglitazone and troglitazone, respectively. Between 1 and 2 weeks of treatment, MPCCs created with the JNB donor displayed a downregulation of the aforementioned markers even in DMSO-treated controls, which is likely due to the use of a serum-free culture medium that prevents proper fibroblast growth that is necessary to support the phenotype of susceptible PHH donors. However, we used a serum-free drug incubation medium to be consistent with the in vitro drug treatment protocols routinely employed with hepatocyte culture (Khetani et al., 2013; Xu et al.,
2008) towards assessing a drug's effects on cells in the absence of drug binding to bovine proteins at 10% (v/v) that do not mimic the protein concentration in human plasma. Last, the morphology of PHHs within MPCCs was not significantly affected upon drug treatment for 1 week (Figs. 1D-F) as compared with DMSOtreated controls. In particular, PHHs retained prototypical polygonal shape, contained distinct nuclei/nucleoli, and formed visible bile canaliculi under phase contrast microscopy across all treatments. We also confirmed in another PHH donor (HUM4055A) that neither hepatic function, as assessed by albumin secretion (Supplementary Figure 1A) , nor morphology (Supplementary Figure 1B) were affected in MPCCs treated with either troglitazone or rosiglitazone at their respective C max for up to 2 weeks. Therefore, at their respective C max doses, neither rosiglitazone nor troglitazone had adverse effects on PHH phenotype but were still able to induce CYP3A4, which suggests that the cells were able to respond appropriately to the drugs.
Time-dependent gene expression analysis. RNA from pure 3T3-J2s treated with DMSO for 7 days was used to determine murine transcripts that were called "present" on a human Affymetrix GeneChip and thus excluded from further analysis (approximately 18% of the total MPCC transcripts). Next, we identified "differentially expressed genes" as those transcripts with a jfold changej >2.0 and jdifference in expressionj >100 in drug-treated MPCCs relative to DMSO-only controls. All the differentially expressed genes in pure 3T3-J2 cultures after 7 days of treatment with troglitazone at its C max (2.82 mg/ml) relative to DMSOtreated 3T3-J2 cultures did not overlap (not shown) with the differentially expressed genes in troglitazone-treated MPCCs relative to DMSO-treated MPCCs. Thus, the gene expression analysis described below in MPCCs is largely hepatospecific.
After 24 h of treatment, troglitazone at its C max (2.82 mg/ml) exclusively upregulated the expression of 9 genes and downregulated the expression of 1 gene, while rosiglitazone at its C max (0.373 mg/ml) exclusively upregulated the expression of 1 gene as compared with DMSO-treated controls at 24 h ( Figure 2A ). Fatty acid-binding protein 4 (FABP4) was the only transcript upregulated by both troglitazone and rosiglitazone after 24 h of treatment. After 7 days of treatment, troglitazone exclusively upregulated the expression of 118 genes and downregulated the expression of 143 genes, while rosiglitazone exclusively upregulated the expression of 2 genes total as compared with DMSOtreated controls ( Figure 2B ). Additionally, troglitazone and rosiglitazone both upregulated the expression of 4 genes (phosphoglycerate dehydrogenase [PHGDH] , FABP4, MBL2, and CD36), and downregulated the expression of 2 genes (hepcidin antimicrobial peptide and cysteine-rich C-terminal 1). Troglitazone induced higher fold changes for all transcripts affected by both drugs (Supplementary Table 1 ). Last, following 14 days of treatment, troglitazone exclusively upregulated the expression of 256 genes and downregulated the expression of 227 genes, while rosiglitazone exclusively upregulated the expression of 13 genes and downregulated the expression of 5 genes as compared with DMSO-treated controls ( Figure 2C ). Moreover, both troglitazone and rosiglitazone upregulated the expression of 106 genes and downregulated the expression of 21 genes. Troglitazone induced a higher fold change for 93% of the All error bars represent standard deviation (n ¼ 3). Hepatic morphology in cultures treated with DMSO (D), rosiglitazone at 0.373 mg/ml (E), or troglitazone at 2.82 mg/ml (F) showed no significant differences after 7 days of treatment. All scale bars represent 250 mm.
overlapping transcripts at day 14 of treatment (Supplementary Table 2 ).
The aforementioned differentially expressed genes were classified further based on their corresponding KEGGs pathways, which are a collection of pathways for molecular interactions and reaction networks. After 24 h of treatment, troglitazone modulated the expression of genes classified in the drug metabolism, linoleic acid metabolism, and retinol metabolism KEGG pathways (Figs. 3A and B, Supplementary Table 3) . Several of these genes corresponded to CYP450 isoforms (2B6, 3A4, 3A7, or 3A43). After 7 days of treatment, troglitazone modulated the expression of genes associated with the primary bile acid biosynthesis, steroid hormone biosynthesis, drug metabolism, linoleic acid metabolism, retinol metabolism, and PPAR (peroxisome proliferator-activated receptor) signaling KEGG pathways (Figs. 3A and B, Supplementary Table 4) . Most of these genes coded for CYP450 enzymes and transporter proteins. Two genes (CD36 and FABP4) were identified in the PPAR signaling KEGG pathway with both troglitazone and rosiglitazone. Last, after 14 days of treatment, troglitazone continued to modulate the expression of genes from all the KEGG pathways identified at 7 days of treatment as well as additional pathways for glycolysis/gluconeogenesis, arachidonic acid metabolism, and amino acid metabolism ( Figs. 3A and B ; Table 1 ). The differentially expressed genes in MPCCs treated with troglitazone or rosiglitazone at their respective C max concentrations were also classified by the GO processes, which are annotations of genes and gene products (Figs. 3C and D) . Some of the transcripts were clustered in the "innate immune response", "inflammatory response", and "response to wounding" GO processes. Typically, troglitazone modulated a greater number of transcripts in the GO processes as compared with the number of transcripts modulated by both drugs.
Gene expression analysis at equal drug doses. The aforementioned gene expression changes could be either due to the higher (by approximately 7.5-fold) C max of troglitazone as compared with the C max of rosiglitazone and/or due to the inherent (dose-independent) effects of troglitazone. Therefore, we treated MPCCs for 7 days with troglitazone or rosiglitazone at the same dose, the C max of troglitazone (2.82 mg/ml). Comparing rosiglitazone at 0.373 mg/ml ( Figure 2B ) and at 2.82 mg/ml (Figure 4) , there was a considerable increase in the transcripts that were modulated by rosiglitazone at the higher dose. Specifically, the higher dose of rosiglitazone exclusively upregulated the expression of 10 genes and downregulated the expression of 3 genes, while troglitazone exclusively upregulated the expression of 93 genes and downregulated the expression of 22 genes as compared with DMSO-treated controls at 7 days. Of the genes differentially expressed by both troglitazone and rosiglitazone, 68 were upregulated and 20 were downregulated. Of these overlapping transcripts, 76% had higher fold changes with troglitazone than with rosiglitazone (Supplementary Table 5) .
KEGG pathways identified with the genes differentially expressed by troglitazone and the higher dose of rosiglitazone have roles in drug metabolism and metabolic processes ( Figure  5A , Supplementary Table 6 ). As opposed to treatment with the respective C max of each drug, using an equal dose caused more KEGG pathways to be identified with both troglitazone and rosiglitazone, specifically ones for steroid hormone biosynthesis, drug metabolism, linoleic acid metabolism, retinol metabolism, PPAR signaling, and complement/coagulation cascades. Genes associated with these KEGG pathways code for many CYP450 enzymes and transporters, among other proteins. In addition, troglitazone modulated the expression of more genes from the drug metabolism, retinol metabolism, and complement/coagulation cascades pathways. These genes included CYP450 enzymes (2A6, 2C9, and 2C19) and complement/coagulation factors (C3 and C8A). Rosiglitazone at an equal dose as troglitazone exclusively modulated acyl-coenzyme A oxidase 2 (ACOX2), CYP4A22, and 3-hydroxy-3-methylglutaryl-CoA synthase, member 2 (HMGCS2), all genes that are associated with the PPAR signaling pathway. Interestingly, while identified with troglitazone in the first study (Figs. 3A and B) , the primary bile acid biosynthesis KEGG pathway was not identified with the equal doses. The 3 genes that were initially identified from this pathway (aldo-keto reductase family 1, member D1 [AKR1D1], CYP39A1, and solute carrier family 27, member A5 [SLC27A5]) were divided into being identified with troglitazone exclusively (SLC27A5) and identified with both troglitazone and the higher dose of rosiglitazone (AKR1D1 and CYP39A1). The differentially expressed genes in MPCCs treated with the same concentration of troglitazone or rosiglitazone were also classified into GO processes ( Figure 5B ). Troglitazone modulated a greater number of genes than rosiglitazone in the "fatty acid metabolic", "steroid metabolic", "response to wounding", and "oxidation/ reduction" GO processes.
Consistency of microarray results across independent experiments.
MPCCs created using the same PHH donor (JNB) across two independent experiments were treated with troglitazone (2.82 mg/ ml) and DMSO (0.1% v/v) for 7 days and the gene expression signatures were obtained via Affymetrix microarrays. Both experiments yielded similar numbers of differentially expressed genes by troglitazone relative to DMSO in key KEGG pathways such as primary bile acid biosynthesis, steroid hormone biosynthesis, arachidonic acid metabolism, drug metabolism, linoleic acid metabolism, retinol metabolism, and PPAR signaling (Supplementary Figure 2A) . Furthermore, the absolute fold changes of the genes identified in these KEGG pathways showed a strong correlation across the two experiments (Supplementary Figure 2B) . qPCR validation in another PHH donor. Select transcripts with a high level of upregulation in MPCCs (JNB donor) treated with troglitazone for 7 days as compared with DMSO-treated controls were also validated via qPCR using another cryopreserved PHH donor (HUM4043). These genes included SCD, ACSM3, ELOVL2, CD36, and mannose binding lectin 2 (MBL2). Expression of these genes in the second PHH donor using qPCR correlated well with the first PHH donor using microarray analysis (Supplementary Figure 3) . Furthermore, genes that were not flagged as differentially expressed in the microarray analysis were also selected for qPCR validation. In particular, the qPCR analysis showed that FOS, C10orf10, and HMG20B were not modulated >2-fold in troglitazone-treated MPCCs relative to DMSO-treated controls, respectively.
Treatment of MPCCs for 1 Week With 3 Other Pairs of Structural Analog Drugs
MPCCs created using the HUM4055A PHH donor (since the JNB PHH donor used for treatment with troglitazone or rosiglitazone was no longer available from BioreclamationIVT) were treated for 1 week with 3 other pairs of hepatotoxic and non-liver-toxic structural analog drugs at their respective C max values, namely nefazodone (434.55 ng/ml) and buspirone (2.11 ng/ml), ibufenac (19.23 mg/ml) and ibuprofen (31.87 mg/ml), and tolcapone (4.51 mg/ml) and entacapone (1.91 mg/ml). None of these drugs at these doses caused downregulation of either albumin or urea secretion in MPCCs relative to DMSO-treated controls (Supplementary Figure 4) . Furthermore, the morphology of PHHs within MPCCs was not significantly affected by treatment with the aforementioned drug pairs for 1 week (Supplementary Figure 5) . Use of the same filtering criteria for identifying differentially expressed genes as that used for studies with troglitazone and rosiglitazone led to only 17-24 transcripts (vs 269 transcripts with troglitazone and rosiglitazone) across the 3 pairs of drugs relative to DMSO-treated controls (Supplementary Figure 6) after 7 days of treatment, which is likely due to donor-dependent differences across the two experiments. Nonetheless, the hepatotoxin in each pair upregulated the expression of a greater number of genes than the nonliver-toxic analog.
Next, we used a jfold changej > 1.5 and jdifference in expressionj > 50 to identify differentially expressed genes in drug-treated MPCCs relative to DMSO-only controls. Nefazodone at its C max (434.55 ng/ml) exclusively upregulated the expression of 55 genes and downregulated the expression of 33 genes, while buspirone at its C max (2.11 ng/ml) exclusively upregulated the expression of 13 genes and downregulated the expression of 14 genes as compared with DMSO-treated controls at ( Figure 6A ). Both nefazodone and buspirone upregulated the expression of 11 genes and downregulated the expression of 23 genes. Ibufenac at its C max (19.23 mg/ml) exclusively upregulated the expression of 79 genes and downregulated the expression of 92 genes, while ibuprofen at its C max (31.87 mg/ml) exclusively upregulated the expression of 12 genes and downregulated the expression of 5 genes as compared with DMSOtreated controls at ( Figure 6B ). Both ibufenac and ibuprofen upregulated the expression of 11 genes and downregulated the expression of 26 genes. Tolcapone at its C max (4.51 mg/ml) exclusively upregulated the expression of 57 genes and downregulated the expression of 31 genes, while entacapone at its C max (1.91 mg/ml) exclusively upregulated the expression of 9 genes and downregulated the expression of 9 genes as compared with DMSO-treated controls ( Figure 6B ). Both tolcapone and entacapone upregulated the expression of 33 genes and downregulated the expression of 9 genes. Therefore, even with a less conservative filtering criteria, the hepatotoxin in each pair upregulated the expression of a greater number of genes than the non-liver-toxic analog. The aforementioned differentially expressed genes were classified further into KEGG pathways and GO processes. Nefazodone exclusively modulated the expression of genes classified in the leukocyte transendothelial migration, cell adhesion molecules, retinol metabolism, and cancer-related KEGG pathways ( Figure 7A ; Supplementary Table 7) . Ibufenac exclusively modulated the expression of genes classified in the steroid hormone biosynthesis, fatty acid metabolism and biosynthesis, retinol metabolism, tyrosine metabolism, and PPAR signaling pathways ( Figure 7B; Supplementary Table 8 ). Tolcapone exclusively modulated the expression of genes classified in the ECMreceptor interaction and proteoglycans in cancer pathways, while both tolcapone and entacapone modulated the expression of genes classified in the leukocyte transendothelial migration and cell adhesion molecules pathways ( Figure 7C ; Supplementary Table 9 ). Classifying the differentially expressed genes into GO processes also revealed that the hepatotoxic drug in each pair led to a greater number of processes being modulated than the non-liver-toxic structural analog. In particular, nefazodone exclusively modulated the expression of genes classified in the innate immune response, cell motility, and cellular response to chemical stimulus processes. Ibufenac exclusively modulated the expression of genes classified in the steroid metabolic, fatty acid metabolic, lipid metabolic, oxidation-reduction, and response to chemical stimulus/organic substance processes. Finally, tolcapone exclusively modulated the expression of genes classified in the cell-cell signaling and response to chemical stimulus/organic substance processes. Therefore, as observed with troglitazone and rosiglitazone, each hepatotoxin in the 3 other pairs of structural analog drugs led to a greater number of differentially expressed transcripts, KEGG pathways, and GO processes than the corresponding non-liver-toxic structural analog.
DISCUSSION
We demonstrate that exposing functional PHHs within MPCCs to non-toxic doses of drugs (ie, relative C max ) for up to 14 days can be used to distinguish the gene expression signatures induced by clinical hepatotoxins from nonliver-toxic analogs. We used hepatotoxin/non-liver-toxin, troglitazone/rosiglitazone, to determine time-and dose-dependent effects on global gene expression patterns in MPCCs, and then nefazodone/buspirone, ibufenac/ibuprofen, and tolcapone/entacapone to further determine MPCC utility for such analysis.
A serum-free dosing medium caused a decline in baseline MPCC functions over time in select PHH donors, potentially due to insufficient fibroblast growth for optimally supporting the phenotype of sensitive PHH donors. Nonetheless, functions and gene expression levels were detected at sufficiently high levels in serum-free conditions to enable 14 days of drug treatment. Indeed, consistent with the short-term treatment of PHHs (Doshi and Li, 2011) , troglitazone and rosiglitazone induced CYP3A4 activity in MPCCs even after 14 days of incubation. More broadly, treating MPCCs with drugs in a serum-free medium allows improved clinical prediction for drug clearance , metabolite identification (Wang et al., 2010) , and hepatotoxicity relative to PHH monolayers.
Although a serum-free medium is widely used to investigate the intrinsic effects of drugs on cells (Chan et al., 2013; Gerets et al., 2012) , it does not mimic drug binding to human plasma proteins and how such binding may influence the unbound intracellular drug concentration that affects cellular processes (Zhang et al., 2012a) . The presence of uptake/efflux transporters in PHHs can lead to further changes in intracellular drug concentrations . The use of undiluted human plasma on polarized PHHs can mitigate such a limitation; however, the effects of human plasma batches of different compositions and quality on the levels/longevity of PHH functions over weeks needs to be investigated. Nonetheless, our use of the C max for each drug approximates the relative differences in potencies across analogs, which can be extended to the predicted efficacious concentrations at the portal triad of the liver sinusoid for preclinical compounds.
Fibroblasts can be detached from MPCCs via selective trypsinization while leaving adherent PHH islands intact (Khetani and Bhatia, 2008 ); however, since the level of hepatic purity is dependent on the state of drug-treated hepatocytes, we did not use this method here. Fluorescence-activated cell sorting was also not used since the time required can potentially modulate gene expression. Instead, we excluded from analysis those transcripts that were called present when pure 3T3-J2 murine RNA was hybridized to the human microarray (approximately 18% of the total MPCC transcripts). Furthermore, the differentially expressed genes from a human microarray in pure 3T3-J2 cultures treated with troglitazone for 1 week as compared with cultures treated with DMSO did not overlap with differentially expressed genes in MPCCs treated under identical conditions. Ultimately, RNA sequencing can help exclude those sequences that map to the mouse genome, and also reveal novel drugmodulated transcripts. However, microarrays are currently a more cost-effective solution with straightforward bioinformatics analysis for obtaining an assessment of the drug's effects on known transcripts. After 1 day of treatment with troglitazone or rosiglitazone, 12 genes were differentially expressed (jfold changej > 2.0 and jdifference in expressionj > 100 relative to DMSO). Of these, the transcript upregulated by both drugs was FABP4, a target gene of PPARc (Boss et al., 2015) , the nuclear receptor to which both drugs can bind. Rosiglitazone exclusively modulated 1 FIG. 6 . Global gene expression changes in MPCCs treated with additional clinical hepatotoxic/non-liver-toxic drug pairs at their respective Cmax levels for 7 days. A, The number of genes upregulated or downregulated (jfold changej > 1.5 and jdifference in expressionj > 50) in MPCCs (HUM4055A donor) by nefazodone (434.55 ng/ml) or buspirone (2.11 ng/ml) or both these drugs relative to DMSO after treatment for 7 days. B, Similar analysis as in panel (A) except MPCCs were treated with ibufenac (19.23 mg/ml) or ibuprofen (31.87 mg/ml). C, Similar analysis as in panel 'A' except MPCCs were treated with tolcapone (4.51 mg/ml) or entacapone (1.91 mg/ml).
FIG. 5.
Pathway and GO process analysis for differentially expressed genes in MPCCs treated with troglitazone or rosiglitazone at the same concentration for 7 days.
The number of differentially expressed genes across (A) KEGG pathways and (B) GO processes in MPCCs (JNB donor) by troglitazone (2.82 mg/ml) or rosiglitazone (2.82 mg/ml) or both drugs relative to DMSO after treatment for 7 days. nonprotein-coding transcript, while troglitazone exclusively modulated 10 transcripts involved in retinol metabolism, drug metabolism, linoleic acid metabolism, and steroid hormone biosynthesis. In contrast to 1 day, 7 days of treatment led to 261 transcripts being exclusively modulated by troglitazone in biosynthetic (primary bile acids and steroid hormone) and metabolic (ie, amino acid, arachidonic acid, drug, fatty acid, and retinol metabolism) pathways. The troglitazone-mediated modulation of bile acid biosynthesis, fatty acid metabolism, and drug metabolism, in particular, are potentially indicative of a stress on bile acid homeostasis in PHHs, mitochondrial dysfunction, and oxidative stress caused by the generation of reactive metabolites, respectively, all suspected mechanisms of troglitazone-induced hepatotoxicity (Jaeschke, 2007; Yang et al., 2014) . Additionally, select troglitazone-modulated transcripts clustered into the "wound healing" GO process (ie, CD36, BMP2 or bone morphogenetic protein 2, CXCL2 or chemokine (C-X-C motif) ligand 2). Rosiglitazone exclusively modulated 2 transcripts (hypothetical proteins), while PPAR signaling was identified with both drugs.
After 14 days of treatment, both troglitazone and rosiglitazone modulated 127 transcripts in biosynthetic and metabolic pathways, but troglitazone modulated 93% of these transcripts with higher fold changes than rosiglitazone. For instance, troglitazone caused an approximately 39-and 29-fold upregulation in CYP2C8 and CYP3A4, respectively, as compared with approximately 12-and 4-fold by rosiglitazone. Reactive metabolites of troglitazone formed by CYP2C8 and CYP3A4 are implicated in hepatotoxicity (Kassahun et al., 2001; Usui et al., 2011) . Furthermore, troglitazone exclusively modulated 483 transcripts as opposed to 18 transcripts exclusively modulated by rosiglitazone. For instance, troglitazone exclusively modulated an additional 15 transcripts involved in drug metabolism (ie, CYP2C19, FMO3 or flavin-containing monooxygenase 3). FMOs have been shown to produce endogenous hydrogen peroxide (Siddens et al., 2014) , which may be responsible for oxidative stress. Last, troglitazone exclusively modulated an additional 18 transcripts in the "complement and coagulation cascades" pathway (ie, C2, C3, and C8B or complement component 2, 3, and 8B were each upregulated). Complement proteins/coagulation factors may be a repair mechanism in response to hepatic damage (Qin and Gao, 2006) . In humans treated with troglitazone, C3 protein is elevated (Ebeling et al., 1999) and may be indicative of an injury response FIG. 7 . Pathway and GO process analysis for differentially expressed genes in MPCCs treated with additional clinical hepatotoxic/non-liver-toxic drug pairs at their respective Cmax levels for 7 days. A, The number of differentially expressed genes across KEGG pathways (top) or GO processes (bottom) that are modulated in MPCCs (HUM4055A donor) by nefazodone (434.55 ng/ml) or buspirone (2.11 ng/ml) or both these drugs relative to DMSO after treatment for 7 days. B, Similar analysis as in panel (A) except MPCCs were treated with ibufenac (19.23 mg/ml) or ibuprofen (31.87 mg/ml). C, Similar analysis as in panel (A) except MPCCs were treated with tolcapone (4.51 mg/ml) or entacapone (1.91 mg/ml).
to oxidative stress or related cellular damage, similar to the implicated role of complement activation in acetaminopheninduced hepatotoxicity (Singhal et al., 2012) .
When MPCCs were treated with troglitazone or rosiglitazone for 7 days at 2.82 mg/ml (C max of troglitazone), 88 transcripts were modulated by both drugs as compared with 6 transcripts modulated by the drugs at their respective C max . The corresponding pathways identified for both drugs at 2.82 mg/ml were primarily in steroid hormone biosynthesis and metabolism (drug, linoleic acid, and retinol). However, over half of the total identified transcripts were still flagged with troglitazone exclusively (ie, ARG1 or arginase 1, C8A, FMO3, GSTM1 or glutathione S-transferase mu 1, and SULT1A1 or sulfotransferase family 1A member 1). C3 was not flagged as differentially expressed at the elevated dose of rosiglitazone, but it was flagged when cultures were dosed with troglitazone. Therefore, troglitazone's effect on PHH transcripts is partly due to its inherent properties as opposed to a higher C max than rosiglitazone.
In order to determine if results obtained with troglitazone/ rosiglitazone extended to other drug pairs, we incubated MPCCs created with another PHH donor (given limitations in the availability of the previous donor) for 7 days with hepatotoxic/nonliver-toxic drug pairs: nefazodone/buspirone, ibufenac/ ibuprofen, and tolcapone/entacapone. However, in contrast to the 269 differentially expressed genes identified with troglitazone/rosiglitazone, the other drugs caused 17-24 genes to be differentially expressed using the same filtering criteria (jfold changej > 2.0 and jdifference in expressionj > 100). Therefore, we made the filtering criteria less conservative (jfold change-> 1.5 and jdifference in expressionj > 50) to obtain the number of differentially expressed genes by the additional drug pairs on the same magnitude as for troglitazone/rosiglitazone. Nonetheless, both filtering criteria showed that the hepatotoxins exclusively modulated a greater number of transcripts than their non-liver-toxic analogs. In particular, nefazodone, ibufenac, and tolcapone exclusively modulated 59% (out of 149), 76% (out of 225), and 59% (out of 148) of the total number of differentially expressed genes in MPCCs relative to DMSO, respectively. On the other hand, buspirone, ibuprofen, and entacapone exclusively modulated 18%, 8%, and 12% of the transcripts, respectively. Interestingly, ibufenac modulated transcripts in pathways that were also modulated by troglitazone (ie, retinol metabolism, fatty acid metabolism, and steroid hormone biosynthesis). The aforementioned difference in filtering criteria needed for troglitazone/rosiglitazone versus the other drug pairs is potentially due to the differential sensitivities of PHH donors to the effects of drugs (as in the clinic), which merits future investigation using additional donors.
Although we sought to study the chronic effects of analog drugs on PHH gene expression, liver NPCs can also experience drug toxicity and/or secrete molecules that affect PHHs . Although we have yet to find another liver-or non-liver cell type that can induce higher levels of functions in PHHs than 3T3-J2 fibroblasts (manuscript in preparation), we have cultured liver NPCs (ie, Kupffer macrophages) within the 3T3-J2 layer surrounding the PHH colonies with optimal dimensions and validated known PHH-NPC interactions (Nguyen et al., 2015) . Such liver NPC-modified MPCCs can potentially also be useful for TGx analysis with comparison to unmodified MPCCs.
In conclusion, hepatotoxins modulated a greater number of transcripts, often with higher fold changes, across diverse pathways/processes than their non-liver-toxic analogs in PHHs within MPCCs that were treated for up to 14 days with drugs at their respective C max values. In the future, complementing gene expression profiling in MPCCs with proteomics and metabolomics could enable insights into DILI pathogenesis at multiple levels.
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